Thank you, Fredrik. Indeed, Q2 was a record quarter, and I'm pleased to guide you through some of the updates and the outlook to give you the gist and the understanding that, in fact, we're just getting started on embarking on new endeavors starting June 17th. If you turn to the next lone tone, we announced that we have expanded the agreement with Thermo Fisher to now cover global territory.
We initially hesitated to give Thermo Fisher access to global territory for our transplantation products a year ago when we first signed the agreement with them, because we wanted to ensure that customers responded positively to the collaboration and confirm the investments and dedication made by Thermo Fisher. We have now seen positive responses and hence are now working with them to build significant global success. Our products have long been advocated for by key opinion leaders, and we are now seeing laboratories begin incorporating these products into their clinical routines across both Europe and North America. We are confident that this momentum will only increase once we onboard users from Asia-Pacific as well.
Granting Thermo Fisher access to our global markets is strategically beneficial for the revenue growth of Devyser, as we can now expand our market reach by an additional 43%, measured by the number of kidney transplants in the Asia Pacific region. Together with Thermo Fisher, we are targeting a market worth over 1 billion US dollars and have already made significant progress in establishing new market standards using the Devyser One Lambda post-transplantation products. We have already achieved the first IVDR approvals for both our assays and software. We are actively seeking FDA approval in the US and are on a solid path towards also having our tests reimbursed in our CLIA-certified laboratory. You can move to the next slide, focusing on the revenue logic related to our global partnership. This equally helps with cost synergies. Since we no longer need to maintain a product line exclusively for transportation products, including taking them through regulatory approvals, etc., these efforts will now be focused solely on the Thermo Fisher co-branded product line. Hence, this is truly a sound business decision. As we now look into year two and onwards.
Together with Thermo Fisher, we are intrigued by the opportunities ahead, not least in the product pipeline front where we have several new and potentially groundbreaking product launches coming up. While these products are not automatically included in the master agreement we have with Thermo Fisher, we do believe that these products will significantly enhance both Thermo Fisher's and our position within the transportation sector for the years to come. Let's move to Italy during Q2. We closed deals worth 84 million Swedish kronor in Italy, including an all-time high tender covering the region of Tuscany. We continued the expansion of our oncology business as well, as we won another deal for our telomere product.
If you add the announcement that we made late last week, that number is close to 90 million Swedish kronor in the past 3 to 4 months. Italy remains our largest market, and I'm thrilled to see how the team continues to take market share and expand our business. Looking ahead, I'm excited to see that we still have a large number of opportunities to further accelerate this momentum. I'm sure that a lot more will come. Focusing on Thalassemia, which is one of the most prevalent hereditary diseases in the world.
The market is therefore huge, and Devyser is well positioned. We are well positioned with our product, which grew almost 60% during the first half of this year compared to the same period last year, and now accounts for about 10% of our total sales. We're pursuing a large number of opportunities in markets where the prevalence of Thalassemia is high, such as Italy, Spain, Saudi Arabia, Malaysia, India, and Singapore, and I could go on. Recently, our smear test was chosen for a state screening program in California, US, and we are pursuing other similar state programs within the US as well.
Lastly, I can share that we are in dialogue with large pharmaceutical companies who have expressed interest in the product as well, and I will soon come back with more information about these potential engagements in the months ahead. Another interesting product is our test, where we have seen a lot of strong traction. We continue to expand our market position, and we just signed up with another leading laboratory in Canada in addition to Hymer, Quebec, which we had previously announced. In addition, we announced in December that our RC test was chosen for nationwide screening in Wales, adding yet another country to the list where our test is chosen for either state, regional, or nationwide screening.
One of the markets yet to be penetrated for testing is the US. Where is the market standard still the prophylactic injection for pregnant women? However, just recently the prophylactic drug program experienced a shortage by the suppliers, and thus we now are seeing a significant uptake of requests for testing in the US. I have been very bullish about our market opportunity for this product in the US, and now, especially since the market is turning towards testing before injection, I am even more optimistic about its potential. These days, we are in dialogue with some of the largest laboratory chains and laboratories in the US concerning our RHD tests, and I'm hopeful that one or several of these opportunities will materialize during this year.
I'm excited to be communicating soon about this. Let's move into our next update, regarding what the future holds with Thermo Fisher. We are now one year in, and we're already seeing strong growth, currently up some 65% above H2 2023 with lead times, as we have previously discussed, ranging from 12 to 18 months. We are just at the beginning of our growth journey with Thermo Fisher, and we are confident that this partnership will accelerate in the months and years to come. We're adding three new indications: heart, liver, and lung. We're pursuing FDA clearance and launching groundbreaking new products for the care of transplantation patients globally. These additional three indications will expand our addressable market measured by the total number of transplantations performed globally, as mentioned earlier. This is an exhilarating time in the field of transplantation, and I'm absolutely sure that Devyser will become a key player for many years within this dynamic area. Looking at what's next in the U.S., we continue to capitalize on the opportunities within testing for cystic fibrosis following updated guidelines from the previous year. Our first customer is soon transitioning to clinical routine, and more opportunities are already in the pipeline.
RHD, as mentioned, looks very promising, and I'm confident that this will be an excellent product for the U.S. market in the upcoming years. Additionally, we are gaining traction in Canada. This product has the potential to become one of our best-selling products in the company. In the U.S., 15% of the population is RHD negative, meaning that, across the 3.7 million new births annually, there's a patient population of 550,000 patients annually who should be tested for their fetal status, representing a significant opportunity for Devyser. Now, with the growing interest in RHD testing rather than defaulting to the prophylactic treatment device, we see new opportunities emerging. Genomic Laboratories, our CLIA-certified laboratory in Atlanta, is performing well. We are on track towards having our first products reimbursed and covered, as well as our engagement with the UK-based oncology company, furthering our collaboration. it is progressing well and the laboratory is fulfilling its objectives as a growth catalyst for Devyser within just a few years in the U.S. I'm confident that our business in North America will become the largest region for us, even surpassing our otherwise large and strongly performing market in Italy.
With that, I hand it back to you.